Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
20.4
USD
|
-3.68%
|
|
-5.51%
|
+158.56%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
125.1
|
388.7
|
22.3
|
88.03
|
307.7
|
-
|
-
|
Enterprise Value (EV)
1 |
125.1
|
304
|
-15.95
|
88.03
|
90.75
|
307.7
|
307.7
|
P/E ratio
|
-1.94
x
|
-2.92
x
|
-0.47
x
|
-1.28
x
|
-4.1
x
|
-5.15
x
|
-3.98
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
49
x
|
170
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
49
x
|
170
x
|
EV / EBITDA
|
-
|
-8,339,116
x
|
345,718
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-8.42
x
|
0.34
x
|
-
|
-1.3
x
|
-3.95
x
|
-3
x
|
FCF Yield
|
-
|
-11.9%
|
291%
|
-
|
-77.1%
|
-25.3%
|
-33.3%
|
Price to Book
|
-
|
4.27
x
|
0.5
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
1,250
|
4,952
|
4,618
|
11,158
|
15,086
|
-
|
-
|
Reference price
2 |
100.1
|
78.50
|
4.829
|
7.890
|
20.40
|
20.40
|
20.40
|
Announcement Date
|
6/8/21
|
3/18/22
|
3/8/23
|
3/4/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
6.286
|
1.809
|
EBITDA
|
-
|
-36.46
|
-46.13
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-36.83
|
-51.2
|
-68.86
|
-75.01
|
-80.43
|
-103
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-1,279.6%
|
-5,693.02%
|
Earnings before Tax (EBT)
1 |
-
|
-30.64
|
-37.68
|
-64.46
|
-70.96
|
-74.52
|
-101.1
|
Net income
1 |
-31.67
|
-30.64
|
-37.68
|
-64.46
|
-70.96
|
-74.52
|
-96.02
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-1,185.52%
|
-5,308.96%
|
EPS
2 |
-51.70
|
-26.90
|
-10.30
|
-6.180
|
-4.976
|
-3.963
|
-5.120
|
Free Cash Flow
1 |
-
|
-36.11
|
-46.43
|
-
|
-69.99
|
-77.88
|
-102.5
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-1,238.98%
|
-5,669.34%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
6/8/21
|
3/18/22
|
3/8/23
|
3/4/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-12.44
|
-11.87
|
-
|
-17.55
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-10.08
|
-12.08
|
-12.78
|
-11.96
|
-12.71
|
-13.75
|
-13.95
|
-17.83
|
-19.36
|
-17.72
|
-18.21
|
-18.32
|
-18.7
|
-19.28
|
-16.07
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-3.412
|
-9.057
|
-2.207
|
-10.4
|
-11.86
|
-13.21
|
-14.26
|
-16.08
|
-17.54
|
-16.58
|
-17.24
|
-17.12
|
-17.68
|
-18.38
|
-16.07
|
Net income
1 |
-3.412
|
-9.057
|
-2.207
|
-10.4
|
-11.86
|
-13.21
|
-14.26
|
-16.08
|
-17.54
|
-16.58
|
-17.24
|
-17.12
|
-17.68
|
-18.38
|
-16.07
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.9020
|
-2.500
|
-0.6000
|
-2.900
|
-3.200
|
-3.600
|
-1.600
|
-1.500
|
-1.600
|
-1.500
|
-1.182
|
-1.138
|
-1.162
|
-1.115
|
-0.8300
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/12/21
|
3/18/22
|
5/12/22
|
8/12/22
|
11/10/22
|
3/8/23
|
5/12/23
|
8/11/23
|
11/9/23
|
3/4/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
84.7
|
38.3
|
-
|
217
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-36.1
|
-46.4
|
-
|
-70
|
-77.9
|
-103
|
ROE (net income / shareholders' equity)
|
-
|
-78.3%
|
-71.4%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
18.40
|
9.690
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-29.60
|
-12.60
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
2.43
|
0.58
|
0.27
|
0.27
|
0.49
|
0.59
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
7.74%
|
32.76%
|
Announcement Date
|
6/8/21
|
3/18/22
|
3/8/23
|
3/4/24
|
-
|
-
|
-
|
Last Close Price
20.4
USD Average target price
64
USD Spread / Average Target +213.73% Consensus |
1st Jan change
|
Capi.
|
---|
| +158.56% | 308M | | +25.83% | 661B | | +27.00% | 566B | | -6.76% | 352B | | +20.34% | 332B | | +3.00% | 283B | | +13.09% | 231B | | +5.46% | 200B | | -9.61% | 195B | | -6.26% | 145B |
Other Pharmaceuticals
|